

Tobacco Control Research Branch (TCRB)

tobaccocontrol.cancer.gov

Funding Opportunity Announcements (FOAs)

August 2019

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

[PAR-19-309 \(R21\)](#)

The purpose of this FOA is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.

Expiration: September 8, 2022

NCI Contact: Tanya Agurs-Collins, 240-276-6956, Tanya.Agurs-Collins@nih.gov



Notice to Study the Population Impact(s) of the Court-Ordered, Tobacco-Related Corrective Statements (R21 Clinical Trial Optional)

[PAR-19-064 \(R21\)](#)

The purpose of this notice is to inform potential applicants that NCI is participating in PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional). The PAR has been modified to include the following language in the Full Text of the Announcement: "In addition to research areas already listed in this Section, the [NCI] is interested in applications describing research projects that will address an extraordinary opportunity in this area by utilizing natural experiment, observational, or ecological designs to study the population impact(s) of the court-ordered, tobacco-related corrective statements implemented as part of the Department of Justice's racketeering case, "United States v. Philip Morris USA, Inc.," on television and in newspapers, on tobacco company Web sites and cigarette pack inserts, and possibly at point-of-sale."

Expiration: November 9, 2021

NCI Contact: Kelly Blake, 240-281-5934, Kelly.Blake@nih.gov

Tobacco Use and Human Immunodeficiency Virus (HIV) in Low and Middle Income Countries (LMICs) (R01 and R21 Clinical Trial Optional)

[PAR-18-023 \(R01\)](#), [PAR-18-022 \(R21\)](#)

The purpose of these FOAs is to encourage research focused on tobacco use and HIV infection in LMICs. In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV-positive populations, including those with comorbidities such as tuberculosis, in low-resource settings.

Expiration: January 8, 2020

NCI Contact: Mark Parascandola, 240-276-6871, Mark.Parascandola@nih.gov

U.S. Tobacco Control Policies to Reduce Health Disparities (R01 and R21 Clinical Trial Optional)

[PAR-18-675 \(R01\)](#), [PAR-18-674 \(R21\)](#)

These FOAs are intended to stimulate scientific inquiry focused on innovative tobacco control policies, with the long-term goal of reducing disparities in health outcomes focused on excess disease burden of tobacco use. The policy approaches funded by these FOAs may be existing ones studied to understand how to improve their effectiveness to reduce health disparities, or they may be new policy approaches to reduce health disparities in tobacco use. This initiative includes a special emphasis on engaging critical community partners in the research and proactively disseminating and implementing research findings. This initiative will support observational or intervention research focused on reducing health disparities in tobacco use in the U.S.

Expiration: June 16, 2020

NCI Contact: Bob Vollinger, 240-276-6919, Bob.Vollinger@nih.gov and Annette Kaufman, 240-276-6706, Annette.Kaufman@nih.gov

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

[PAR-18-869 \(R01\)](#)

This FOA encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Expiration: March 9, 2021

NCI Contact: Scott Rogers, 240-276-6932, Scott.Rogers@nih.gov

National Institutes of Health (NIH) Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[PA-19-056 \(R01\)](#)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers based on their scientific missions. PA-19-056 does not accept applications proposing clinical trial(s).

Expiration: January 8, 2022

NCI Contact: Michele Bloch, 240-276-6878, Michele.Bloch@nih.gov

www.cancercontrol.cancer.gov/brp/funding/funding-opportunities.html#tcrb

(more)

Tobacco-Related FOAs Led by Other NIH Institutes/Centers*

Tobacco Regulatory Science (R01 Clinical Trial Optional)

[RFA-OD-19-019 \(R01\)](#)

The purpose of this FOA is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Expiration: February 14, 2021

NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

NEW!

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)

[RFA-OD-19-022 \(R21\)](#)

The purpose of this FOA is to invite applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the FDA CTP. Other publicly available datasets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative datasets will need to provide justification why the dataset is unique, and why the research questions cannot be answered from a (publicly available) nationally representative dataset. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the U.S.

Expiration: March 9, 2021

NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

NEW!

Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

[RFA-OD-19-021 \(R21\)](#)

The purpose of this FOA is to invite applications to stimulate exploratory research relevant to the mission of the FDA CTP using existing (publicly available) biospecimens currently stored in repositories in the United States. Proposed research should seek to maximize the scientific value of stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the dataset is unique, and the research questions cannot be answered from a publicly available, nationally representative, dataset. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Expiration: March 9, 2021

NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

NEW!

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01 and R21 Clinical Trial Not Allowed)

[PAR-19-162 \(R01\)](#), [PAR-19-163 \(R21\)](#)

The ABCD Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the National Institute of Mental Health Data Archive. The purpose of this FOA is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development.

Expiration: September 8, 2021

NCI Contact: Annette Kaufman, 240-276-6706, Annette.Kaufman@nih.gov

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)

[PAR-18-847 \(R01\)](#)

The intent of this FOA is to encourage researchers to generate data to address gaps in our understanding of population-based, clinical and applied prevention of disease related to ENDS. NCI is particularly interested in studies that seek to understand determinants of risk and protective factors related to the trajectories of ENDS use patterns, how ENDS use may influence intentions to quit and cessation of tobacco products, and intervention and policy approaches to address ENDS use among adolescents, young adults, and other vulnerable populations. Studies are encouraged that investigate potential contributions to cancer risk from ENDS use or through the use of ENDS with other tobacco products (dual/poly tobacco use).

Expiration: June 28, 2020

NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01, R21, and R03 Clinical Trial Not Allowed)

[PA-17-135 \(R01\)](#), [PA-17-132 \(R21\)](#), [PA-17-134 \(R03\)](#)

The purpose of these FOAs is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol, marijuana, and other drugs. These FOAs are intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health.

Expiration: May 8, 2020

NCI Contact: Carolyn Reyes-Guzman, 240-276-7244, Carolyn.Reyes-Guzman@nih.gov

**Not a comprehensive list of all tobacco-related FOAs; please consult the NIH Guide for all available funding opportunities.*